상세 보기
EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
- Lencioni, Riccardo;
- Kudo, Masatoshi;
- Erinjeri, Joseph;
- Qin, Shukui;
- Ren, Zhenggang;
- ... Tak, Won Young;
- 외 14명
Citations
WEB OF SCIENCE
138키워드
261-2388-2665-6735; 283-424-425; 613-225-313; 613-225-3248-9559-9794; 3282-3306-7927-3999; 281-318-430; 281-9641-2654-9244-11272; 12; 7; 4; 4; 3; 3; 2; 2018; 182; 2018; 182; 7; 4; 3; 3; 38092-17498; 38092-26368; 11; 1
- 제목
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
- 저자
- Lencioni, Riccardo; Kudo, Masatoshi; Erinjeri, Joseph; Qin, Shukui; Ren, Zhenggang; Chan, Stephen; Arai, Yasuaki; Heo, Jeong; Mai, Ahn; Escobar, Jose; Lopez Chuken, Yamil Alonso; Yoon, Jung-Hwan; Tak, Won Young; Suttichaimongkol, Tanita; Bouattour, Mohamed; Lin, Shi-Ming; Zotkiewicz, Magdalena; Udoye, Stephanie; Cohen, Gordon; Sangro, Bruno
- 발행일
- 2024-01-20
- 유형
- Meeting Abstract
- 권
- 42
- 호
- 3_SUPPL
- 페이지
- LBA432 ~ LBA432
- 언어
- ENG
- 출판사
- LIPPINCOTT WILLIAMS & WILKINS
- 발행국가
- 미국
- ISSN
- E 1527-7755
P 0732-183X